Cencora, Inc. (NYSE:COR) Shares Bought by Copeland Capital Management LLC

Copeland Capital Management LLC boosted its stake in Cencora, Inc. (NYSE:COR - Free Report) by 8,730.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 55,365 shares of the company's stock after purchasing an additional 54,738 shares during the quarter. Copeland Capital Management LLC's holdings in Cencora were worth $15,396,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in COR. Norges Bank bought a new position in Cencora in the 4th quarter worth about $478,309,000. Bank of America Corp DE raised its holdings in shares of Cencora by 62.3% in the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock valued at $1,166,944,000 after acquiring an additional 1,994,256 shares in the last quarter. Castlekeep Investment Advisors LLC purchased a new stake in Cencora in the fourth quarter worth approximately $399,508,000. GAMMA Investing LLC lifted its holdings in shares of Cencora by 43,561.9% in the 1st quarter. GAMMA Investing LLC now owns 1,598,461 shares of the company's stock worth $444,516,000 after acquiring an additional 1,594,800 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Cencora in the 4th quarter worth approximately $322,460,000. Institutional investors own 97.52% of the company's stock.

Cencora Trading Down 0.4%

COR traded down $1.13 on Monday, reaching $298.29. 468,694 shares of the company traded hands, compared to its average volume of 1,500,508. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The firm has a fifty day simple moving average of $289.95 and a two-hundred day simple moving average of $265.45. The company has a market cap of $57.82 billion, a P/E ratio of 34.61, a price-to-earnings-growth ratio of 1.48 and a beta of 0.58. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.80 earnings per share. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.74%. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Wall Street Analyst Weigh In

A number of research firms recently commented on COR. Bank of America upped their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. UBS Group upped their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Morgan Stanley set a $288.00 price objective on shares of Cencora in a research note on Tuesday, April 15th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $306.33.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares of the company's stock, valued at $89,027,442.53. This trade represents a 4.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the sale, the chief executive officer now directly owns 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,127 shares of company stock worth $9,812,296. Company insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.